All questionsPharmacology: Mounjaro (tirzepatide), all indications5 questions · 2 sourcesMechanismHow does Mounjaro work (mechanism of action)?“Tirzepatide is a GIP receptor and GLP-1 receptor agonist. It contains a C20 fatty diacid that enables albumin binding and prolongs the half-life. Tirzepatide selectively binds to and activates both the GIP and GLP-1 receptors, the targets for native GIP and GLP-1. Tirzepatide enhances first- and second-phase insulin secretion, and reduces glucagon levels, both in a glucose-dependent manner.” (opens the source at this quote in a new tab)CopyFlag“Tirzepatide lowers fasting and postprandial glucose concentration, decreases food intake, and reduces body weight in patients with type 2 diabetes mellitus.” (opens the source at this quote in a new tab)CopyFlag“Tirzepatide increases insulin sensitivity, as demonstrated in a hyperinsulinemic euglycemic clamp study after 28 weeks of treatment.” (opens the source at this quote in a new tab)CopyFlag“Tirzepatide reduces fasting and postprandial glucagon concentrations. Tirzepatide 15 mg reduced fasting glucagon concentration by 28% and glucagon AUC after a mixed meal by 43%, compared with no change for placebo after 28 weeks of treatment.” (opens the source at this quote in a new tab)CopyFlag“Tirzepatide delays gastric emptying. The delay is largest after the first dose and this effect diminishes over time. Tirzepatide slows post-meal glucose absorption and reduces postprandial glucose.” (opens the source at this quote in a new tab)CopyFlagHow is Mounjaro different from a GLP-1 receptor agonist?“The native incretin hormones—GIP and GLP-1—bind to their respective receptors on beta cells in the pancreas to enhance insulin release. Mounjaro is a single peptide designed from the structure of native GIP and modified to bind to the GIP and GLP-1 receptors. While the activity of Mounjaro on the GLP-1 receptor is lower than the activity of the native GLP-1 hormone, the activity of Mounjaro on the GIP receptor is similar to that of the native GIP hormone.” (opens the source at this quote in a new tab)CopyFlagOn the page, select: Video transcript“Tirzepatide is based on the GIP sequence and contains aminoisobutyric acid (Aib) in positions 2 and 13, a C-terminal amide, and Lys residue at position 20 that is attached to 1,20-eicosanedioic acid via a linker. The molecular weight is 4813.53 Da and the empirical formula is C225H348N48O68.” (opens the source at this quote in a new tab)CopyFlagNote: The first passage is from the video transcript on the How Mounjaro Works page of the Mounjaro HCP site; the second is from the Description section of the Prescribing Information.PharmacokineticsHow is Mounjaro metabolized?“Metabolism Tirzepatide is metabolized by proteolytic cleavage of the peptide backbone, beta-oxidation of the C20 fatty diacid and amide hydrolysis. Excretion The primary excretion routes of tirzepatide metabolites are via urine and feces. Intact tirzepatide is not observed in urine or feces.” (opens the source at this quote in a new tab)CopyFlagWhat is the half-life of Mounjaro?“The apparent population mean clearance of tirzepatide is 0.061 L/h with an elimination half-life of approximately 5 days, enabling once-weekly dosing.” (opens the source at this quote in a new tab)CopyFlag“It contains a C20 fatty diacid that enables albumin binding and prolongs the half-life.” (opens the source at this quote in a new tab)CopyFlag“Steady-state plasma tirzepatide concentrations were achieved following 4 weeks of once weekly administration.” (opens the source at this quote in a new tab)CopyFlag“Following subcutaneous administration, the time to maximum plasma concentration of tirzepatide ranges from 8 to 72 hours. The mean absolute bioavailability of tirzepatide following subcutaneous administration is 80%. Similar exposure was achieved with subcutaneous administration of tirzepatide in the abdomen, thigh, or upper arm.” (opens the source at this quote in a new tab)CopyFlagComponentsWhat are the inactive ingredients in Mounjaro?“MOUNJARO is a clear, colorless to slightly yellow, sterile solution for subcutaneous use. Each single-dose pen or single-dose vial contains a 0.5 mL solution of 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg of tirzepatide and the following excipients: sodium chloride (4.1 mg), sodium phosphate dibasic heptahydrate (0.7 mg), and water for injection. Each multi-dose vial or single-patient-use KwikPen contains 2.4 mL of solution, which provides 4 doses of 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg of tirzepatide per 0.6 mL. Each dose contains the following excipients: benzyl alcohol (5.4 mg), glycerin (4.8 mg), phenol (1.08 mg), sodium chloride (1.05 mg), sodium phosphate dibasic heptahydrate (0.8 mg), and water for injection. Hydrochloric acid solution and/or sodium hydroxide solution may have been added to adjust the pH. MOUNJARO has a pH of 6.5 to 7.5.” (opens the source at this quote in a new tab)CopyFlag